Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance

Suman C. Nath1,2*, Lane Harper1* and Derrick E. Rancourt1,2*

1 Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2 McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Cell-based therapy (CBT) is attracting much attention to treat incurable diseases. In recent years, several clinical trials have been conducted using human pluripotent stem cells (hPSCs), and other potential therapeutic cells. Various private- and government-funded organizations are investing in finding permanent cures for diseases that are difficult or expensive to treat over a lifespan, such as age-related macular degeneration, Parkinson’s disease, or diabetes, etc. Clinical-grade cell manufacturing requiring current good manufacturing practices (cGMP) has therefore become an important issue to make safe and effective CBT products. Current cell production practices are adopted from conventional antibody or protein production in the pharmaceutical industry, wherein cells are used as a vector to produce the desired products. With CBT, however, the “cells are the final products” and sensitive to physico-chemical parameters and storage conditions anywhere between isolation and patient administration. In addition, the manufacturing of cellular products involves multi-stage processing, including cell isolation, genetic modification, PSC derivation, expansion, differentiation, purification, characterization, cryopreservation, etc. Posing a high risk of product contamination, these can be time- and cost- prohibitive due to maintenance of cGMP. The growing demand of CBT needs integrated manufacturing systems that can provide a more simple and cost-effective platform. Here, we discuss the current methods and limitations of CBT, based upon experience with biologics production. We review current cell manufacturing integration, automation and provide an overview of some important considerations and best cGMP practices. Finally, we propose how multi-stage cell processing can be integrated into a single bioreactor, in order to develop streamlined cGMP-compliant cell processing systems.

Keywords: cell-based therapy, biologics manufacturing, cGMP, genetic engineering, integrated bioprocessing, bioreactor

INTRODUCTION

Human pluripotent stem cells (hPSCs), including embryonic stem cells (ESCs) (Thomson et al., 1998) and induced pluripotent stem cells (iPSCs) (Takahashi et al., 2007) are attractive tools in the field of regenerative medicine because of their ability to self-renew and differentiate into any cell type in the human body. Use of these cells increased exponentially after the discovery of hiPSCs in
Recently, hundreds of biotechnology companies were founded with the mission to treat degenerative diseases using these cells. Age-related macular degeneration (AMD), type I diabetes mellitus, heart failure, Parkinson's disease and spinal cord injury are the most common degenerative diseases being treated with hPSCs (Trounson and McDonald, 2015).

Although hiPSCs are a better source for autologous CBT, they are less preferable for clinical trials because they are less genetically stable than hESCs (Attwood and Edel, 2019). Viral vectors using for iPSC reprogramming integrate into the genome and poses risk of insertional mutagenesis (Baum, 2007). Moreover, genetic modification can cause mutations that associated with cancer (Gore et al., 2011). Evidence of transgene reactivation after iPSC reprogramming also poses risk after transplantation (Galat et al., 2016).

Some clinical studies have already begun using hiPSCs derived from patients. A clinical trial for the treatment of wet AMD has recently been conducted by the Masayo Takahashi group from the Riken Center for Developmental Biology (Reardon and Cyranoski, 2014). Similarly, Jun Takahashi from Kyoto University is also conducting a clinical trial using hiPSCs to treat Parkinson's disease (Cyranoski, 2018). There are also several clinical trials in the United States using hiPSCs for the treatment of various diseases such as β-thalassemia, liver disease, diabetes, etc. and their use is increasing worldwide (Kimbrel and Lanza, 2015).

Since stem CBT trials are proliferating, many clinical studies continue to use both hESCs and hiPSCs. About 8141 CBTs and 1657 stem CBTs were found based upon searches recently performed on clinicaltrials.gov (October, 2020) (ClinicalTrials.gov, 2020). However, as speculated from previous clinical studies, the percentage of success is quiet low. Of the 315 clinical trials carried out, only 0.3% went to Phase 4 (Trounson and McDonald, 2015). The low percentage of clinical trial completion depends on different factors. One of the main factors is the design and implementation of cost-effective, high safety production practices required by regulatory bodies. In addition, multi-dose production costs also hamper the success rate of clinical trials. Since the global revenues from CBT in 2018 were approximately a billion dollars and are forecasted to be in the tens of billions by 2025, a great deal of attention is needed to produce high-quality cells to treat incurable diseases (Davie et al., 2012; PR Newswire, 2019).

The production of stem cell-derived biologics is adapted from the production of conventional pharmaceutical proteins and vaccines. The production of conventional biologics involves the following basic steps: Isolation and identification of raw materials, formulation, filling, packaging and storage, where total processing stops when final products are stored. This provides a very basic model as the production of conventional biologics. Yet CBT products differ in various significant ways. In biologics, cells are used as a platform for the production of desired therapeutic proteins. Cells are discarded after a batch and new cells with the requisite protein expression are used to produce the next batch. Proteins produced in this way are generally stable, uniform, and easily characterized, varying little between batches.

In cell-based therapies, the final products are cells that are sensitive to the physical or chemical attributes of the resident environment and are prone to spontaneous change. Therefore, these considerations must be taken into account when translating from bench to clinic (Roh et al., 2016). The need for CBT products are emerging from various cell lines including chimeric antigen receptor T-cell (CAR-T), retinal pigment epithelial cell, neural cell, hepatic cell, cardiac cell, mesenchymal stem cell (MSCs), ESCs, iPSCs, etc. for treating various degenerative diseases. In this review, we will focus on cell therapy development ranging from unipotent to pluripotent cells, namely, CAR-T cells (unipotent cells), MSCs (multipotent) and iPSCs (pluripotent) (Figure 1).

Since CBT needs much consideration for producing large cell numbers, using conventional cell processing systems makes it more complicated and sometimes impossible. Being a multi-step process that can cause batch variability, inefficiency and low quality of transplantable cells in plate culture, there are too many possibilities for human error. CBT needs to be simplified and made more direct. In this context, we will discuss some of the current limitations of cell production strategies. We will propose how to possibly overcome these limitations by integrating the entire process into a single bioreactor system due to advantages over plate culture (Table 1). We will also discuss how genetic modification- transfection or transduction, reprogramming, differentiation, purification and development of final products in a single bioreactor can be integrated. In this context, we also discuss some basic, high level cGMP considerations for CBT biomanufacturing.

**CONVENTIONAL PRACTICES FOR CBT PRODUCT MANUFACTURING**

As stated earlier, cell processing differs widely from pharmaceutical proteins or vaccine production although current manufacturing practices are based on conventional biologics manufacturing that may not be compatible for CBT (Bennett, 2018; Sterling, 2018). For example, in biologics manufacturing, microorganisms containing genes of interests are expanded and the proteins are isolated and purified for pharmaceutical peptide production (Figure 1) (Overton, 2014; Jozala et al., 2016). The purified proteins are screened for both chemical and biological properties for quality assurance. Chemical screening includes the testing of pH, solubility, percentage of active ingredients, whereas biological screening includes sterility test, endotoxin test, etc. Although biologics production from microorganisms is complicated, it is not as complicated as CBT production from living cells. Regardless, having fewer variables that need to be controlled, biologics production from microorganisms results in standardized and homogenous production of both target peptides and stock cells.

Difficulty in bioprocessing is increased when pharmaceutical proteins are produced using human, animal or plant cells. High-quality products in this case depend on the maintenance of high-quality cells and sterile conditions as these cells are generally less robust in culture, and tend to be more difficult to work with. In
this case, cells transfected with the genes of interest are cultivated for a certain period of time after inoculation from a master cell bank (Lai et al., 2013; Tekoah et al., 2015). After expansion, cells are stored for future use or discarded after collecting the supernatant. The desired proteins or antibodies are separated, purified and concentrated. The isolated products are then checked for physical, chemical or biological properties similar to microbial peptide production to meet the regulatory agency’s criteria through quality assurance. A considerable benefit is that once the protein is produced, it again tends to be much more stable and characterizable compared to cells for CBT.

Stem cell or blood-derived product manufacturing is not as direct as the production of pharmaceutical proteins or vaccines (Figure 1). This is because cells are the product in CBT and they tend to be less robust in the face of perturbations and more vulnerable to changes in cell identity and gene expression. Manufacturing strategies for cell production can vary from source to source and can differ significantly based on autologous or allogeneic transplantation. The main general steps are the acquisition of tissue samples and cell isolation, initial cell purification, selection, activation and transduction, expansion of cells, differentiation, washing, harvesting and formulation, filling and cryopreservation, and finally storage and delivery to clinics (Roh et al., 2016). At every step, quality assurance and consideration for safety and efficacy are important for all CBT products manufactured for clinical application.

CBT products also differ from sources of tissue acquisition and target of diseases treated. For example, in CAR-T therapy, T-cells are isolated from patients’ blood, which contain abnormal levels of inhibitory factors and regulatory cells (Bellone et al., 1999;
Gajewski et al., 2013) as patients are commonly also treated with chemo- and radiotherapies. Accordingly, heterogeneity can occur in the final products, which need much attention during the cell isolation step. Then initial cell culture is done for selection, activation or transduction of specific interest, in this case, the CAR gene. The transduced cells are then expanded in plate culture and stored in the master cell bank.

Cells are also screened for quality, safety and efficacy. Product potency is an important criterion to meet before releasing the product. For example, if a CBT product is applied for the CAR-T related cancer therapy, it needs to be examined for the secretion of cytotoxic cytokines (IFN-γ) and killing of target cells (Dudley et al., 2003). After passing all the steps of quality assurance, cells are stored or delivered to the clinic. Often cells need to be delivered in a timelier manner than other biologics and have a much less stable “shelf life”, which needs to be taken into consideration.

There is a further increase in the magnitude of process complexity, time, labor and cost when moving to CBT production from human hMSCs to hPSCs (Figure 1). MSCs are only slightly more complicated than T-cells. For biologics manufacturing from hMSCs, cells are expanded and stored in master cell banks after isolation and purification from patients’ bone marrow (Ullah et al., 2015). Then cells are genetically modified or expanded and differentiated into specific types of cells.

An interesting possibility being exploited with MSCs is that sometimes cell-derived bi-products can be used for clinical applications. For example, exosomes secreted from MSCs contain autocrine or paracrine signaling components (cytokines, RNAs, etc.) (Pistikun et al., 2004; Valadi et al., 2007; NHLBI, 2009; Chen et al., 2010) and show immunological activities (Lai et al., 2011; Zhang et al., 2013; Lou et al., 2017). For this reason, it’s possible to consider value-added products, or creation of processes that can utilize such a potential secondary resource. MSC-derived exosomes are currently being studied for treating degenerative diseases (Chang et al., 2018; Yin et al., 2019). MSC-derived exosomes have recently been approved by US FDA for treating burn patients (PRWeb, 2018). For using exosomes in clinical applications, hMSCs are expanded and exosomes are purified by ultracentrifugation or size exclusion chromatography from culture medium. The benefit to this is that if the cell therapy itself is cGMP compliant, then it may be possible to have little added effort to extract a secondary cGMP compliant product in the form of exosomes. However, whether clinical applications use cells or cell-derived products, it needs go through a strict quality screening. Since here the product is cells, it needs to pass the in vivo biological tests for quality, efficacy and safety. After confirming the quality assurance, cells are cryopreserved or delivered to clinics.

hPSCs by contrast are very complicated; however, they have many benefits making them an important cell choice for CBT. Being pluripotent, hPSCs have the ability to be differentiated into any cell type in the body. This provides advantages for therapies involving cells, other than T cells or MSCs that are not accessible via biopsy. Unlike T cells or MSCs, hPSCs do not senesce, making them very conducive to cell bio-banking (Zeng, 2007; Koch et al., 2013).

Biologics manufacturing from hESCs is impractical as isolation from human embryos has been unethical in many jurisdictions (Lo and Parham, 2009). Accordingly hESCs have been superseded by hiPSCs, which avoid such ethical barriers. Compared to hESCs which are subject to immune-rejection due to human leukocyte antigen (HLA) expression after differentiation (Taylor et al., 2005), iPSCs provide a better platform for autologous therapy because terminally-differentiated cells can be reprogrammed to desired cells using the four Yamanaka factors.

iPSCs also provide an alternative option of allogeneic treatment by creating haplotype biobank. HLA-typed biobank can help reduce both the rejection of grafted tissue, and the number of cell lines that are required to meet all populations in a given country (Zimmermann et al., 2012). Nakagawa et al. (2011) reported an integration-free iPSCs generation method that provides HLA-typed biobanking which match 20% of Japanese population.

In the case of biologics production from hiPSCs, the current paradigm is that cells are isolated from patients and reprogrammed into iPSCs using Yamanaka factors in conventional plate culture (Takahashi et al., 2007). As the Yamanaka factors contain the proto-oncogene, c-Myc, there are possibilities of increased genetic abnormalities from viral integration (Nakagawa et al., 2008, 2010). Currently, multiple methods of reprogramming of hiPSCs have been developed due to their unique limitations. Some methods that may be currently considered safer involve using mRNA, proteins, or cytokines although they have their own limitations as well, such as poor transduction efficiency (Kim et al., 2009; Warren et al., 2010). It is well established that these methods are less efficient than viral vectors for reprogramming. However, there are some efficient non-integrative viral vector approaches developed recently for reprogramming that we discuss later part of this study.

Depending on the final product and expected timelines, cell expansion is a very important consideration and area for considerable risk management analysis. After reprogramming, the cells are stored in the master cell bank or expanded for differentiation. Due to generally tighter time considerations in manufacture, application, and shelf-life, large-scale expansion is required in a sterile condition based on demand. This requires intensive consideration because it is a major rate-limiting step in the manufacturing of CBT products. The most important considerations for expansion on a large scale are: operational, economic, quality and safety (Table 2).

Before large-scale expansion, it is important to consider operational design (2D or 3D) with manual or automatic operation (Jenkins and Farid, 2015). In order to obtain a large number of cells, bioreactors tend to be far superior to plate culture in total cell production (Table 1). Important parameters for operational consideration are online monitoring and control of process parameters (pH, DO, pCO2, etc.), as well as considering the shortest possible cultivation time. Due to the nature of 2D culture, it is often difficult to implement monitoring and control methods and therefore rely on operator know-how and standardization of process methods (such as changing media daily). However, by utilizing 3D vessels it is
possible to automate or semi-automate monitoring and process parameters via onboard sensors, with the potential for savings in reagents and removing sources of error. For determining medium feeding regimes, a prediction model for medium consumption (glucose and glutamine) and production of toxic materials (lactic acid and ammonium) can be very useful (Galvanauskas et al., 2019). More data and higher quality data can lead to more effective decisions and use of advanced analytical tools. A single-use vessel is also a major operational consideration that increases expansion cost for cell-based products on a large scale. Although single-use vessel reduces contamination risk by eliminating cleaning procedures and its validation, the cost is not rather dominating here as the priority for the product safety is high. Since cellular products are costly, economic considerations are important for medium, efficient cell lines and other indirect utilities. Above all, product quality and safety are the most important consideration that will provide safe and efficient final product for CBT application.

After expansion, cells are harvested by separating them from the culture substratum of plate or microcarrier using enzymatic treatment or by changing temperature or pH (Yang et al., 2010; Guillaume-Gentil et al., 2011; Dou et al., 2012). For harvesting, aggregate culture in bioreactors may not necessarily require a detachment step (Bartosh et al., 2010; Amit et al., 2011; Larijani et al., 2011; Zweigerdt et al., 2011; Nath et al., 2018), however, microcarrier culture in bioreactor requires detachment step. Purified cells are formulated and checked for quality assurance. Quality assurance is carried out in three different stages: microbial contamination, chemical contamination and quality or potency. Microbial contamination is checked with different methods for bacteria, fungus or virus (Rayment and Williams, 2016; Goldring et al., 2011). A 14-day incubation of cell products for bacterial and fungal contamination is the most commonly used sterility test (Khuu et al., 2006; Hocquet et al., 2014). Chemical testing includes checking molecules that accompany the culture medium or other factors used during isolation, expansion and storage. The LAL test for bacterial endotoxin is a common chemical test. An automated 15-min test to determine endotoxin in CBT products has now been developed in accordance with FDA regulations (Gee et al., 2008). Other chemical testing concerns examine residual proteins of different origins, serum and other harmful cell processing particles.

Quality is the main concern in CBT products, especially when cell growth is a requirement. A cell viability test is therefore performed to determine live or dead cells in the product using a variety of staining methods. It is also useful to determine the biological activity of CBT products (Choi et al., 2011; Schellenberg et al., 2013). Pre-release product potency is an important criterion to meet. For example, the final products for hPSCs are differentiated cells, wherein the potency should be checked through transplantation into disease models.

Strict quality control is imperative for products derived from hPSC before transplantation to patients, as there is a high risk of transferring oncogenes to patients. In Japan, a clinical trial was halted in 2015 when treating AMD with autologous retinal pigmented epithelial cells derived from hiPSC due to genetic abnormality (Garber, 2015). Since genetic abnormalities occur in products derived from hiPSCs from reprogramming to finally differentiated cells (Rohani et al., 2014), cells should be screened strictly for epigenetic signatures, karyotype, telomerase activity, and mitochondrial remodeling, and functional assays including teratoma formation and in vitro differentiation (Feng et al., 2010; Kim et al., 2010; Yehezkel et al., 2011; Rohani et al., 2018). Some of the other proposed quality tests include whole-genome sequencing, single-cell genome sequencing, epigenetic analysis, and DNA integrity testing to maximize patient safety.

Cells must be delivered to clinics immediately or stored for future use after the product quality assurance has been passed. If the cells are vitrified, cells are usually shipped to clinics on dry ice (−78°C) or in liquid nitrogen dry shippers (−160°C). The most commonly used cell storage technique is cryopreservation in liquid nitrogen at −196°C, which is adapted from the conventional stem cells banking (Thirumala et al., 2009; Hunt, 2011). For the better recovery of cryopreserved cells, slow-freezing and rapid thawing is generally highly applicable (Kurata et al., 1994; Moon et al., 2008). Recently Celikkan et al. (2019) developed a new media for transporting multipotent stromal cells using Ringer's lactate-based transport media supplemented with human serum albumin that supported more than 90% cell survival after 6 h of transportation. Developing more robust methods and media is also important for long distance cell delivery.

**TABLE 2 | Considerations for large-scale expansion of hPSCs in bioreactor culture.**

| Characteristics                  | What to consider                                      |
|----------------------------------|-------------------------------------------------------|
| Operational considerations       | • Culture system (2D/3D)                               |
|                                  | • Manual or automatic operation                        |
|                                  | • Process control and monitoring (online/offline)      |
|                                  | • Culture environment (temperature, pH, DO, pCO₂ etc.) |
|                                  | • Culture time                                         |
|                                  | • Culture vessel (single/multi-use)                     |
|                                  | • Target final cell density (cells/mL)                  |
|                                  | • Medium feeding regimen (once/twice in a day)         |
|                                  | • Prediction model                                     |
| Economic considerations          | • Medium                                               |
|                                  | • Resources (devices, labor, etc.)                     |
|                                  | • Cell storage (cryopreservation)                      |
|                                  | • Efficient cell lines                                 |
|                                  | • Indirect utilities                                   |
| Considerations for quality and   | • Quality control                                      |
| safety                            | • cGMP compliant                                       |
|                                  | • Efficacy (in vitro and in vivo)                      |
|                                  | • Harvest purity                                       |

**STANDARDIZATION OF BIOLOGICS MANUFACTURING IN BIOREACTORS**

Manufacturing of pharmaceutical proteins or other biological products consists of several steps from raw materials to finished...
products that may significantly compromise the quality of the product. They also reduce productivity and are prone to human errors. Different pharmaceutical companies have attempted integrated pharmaceutical production to overcome these disadvantages. One of the major attempts to fully integrate the cell processing system is being made by the Novartis-MIT Center for Continuous Production of Pharmaceutical Products (Bisson, 2008; Schaber et al., 2011). Genzyme is also attempting to continuously produce pharmaceutical recombinant protein in bioreactors, wherein cell culture is being integrated into a single flow for product isolation and purification (Warikoo, 2011). In order to reduce cumbersome production steps and significantly reduce costs, process integrity is necessary. One such integrated system developed by Johnson and Johnson has recently been approved by the FDA for large-scale production of HIV drugs (FIERCE Pharma, 2016), which have been shown to reduce time and costs by one third compared to conventional batch processing.

The integration of production steps provides high product quality and safety and helps to overcome strict regulatory requirements by easing ability to obtain and retain cGMP compliance. In this context, the next sections will discuss how to integrate certain important basic steps in cell production, in particular genetic modification, cell reprogramming, expansion and differentiation in bioreactors to promote a single step approach for cell-based therapies utilizing T-cells, MSCs, and hPSCs (Figure 2).

### Standardization of Genetic Modifications in Bioreactors

Genetic modification has been applied for production of antibodies, proteins or other biotechnological drugs production for many years in the pharmaceutical industry. It has also been widely used in recent years to treat multiple incurable genetic diseases. For example, in a neurological disorder called adrenoleukodystrophy (ALD), there is a malfunction of oligodendrocytes and microglia, and genetic modification can directly affect disease outcome. A corrected gene is inserted into the patient-derived hPSCs and transplanted into the patient’s brain. The inserted hPSCs differentiate into microglia to promote myelin production in the patient’s brain that affects ALD outcomes (Cartier et al., 2009).

Sometimes patients are exposed indirectly to genetic modification. For example, in thalassemia, patient blood cells are extracted from the body are modified and enriched...
ex vivo in order to target specific antigens in the body of patients (Naldini, 2011). Other indirect genetic changes include modification of CAR or T cell receptors (TCRs) in T-cells (Wang and Riviere, 2015), expression of CD40 ligand in dendritic cells (Kikuchi et al., 2000), etc. Genetically modified CAR-T cells can target antigens specifically and efficiently kill cancer cells (Song, 2013). CARs and TCRs are the most commonly used receptors for the activation of T cells (Kerkar, 2013). Many cell-based CAR-T therapies are now being developed for the treatment of advanced-stage lymphoma (Kochenderfer and Rosenberg, 2013), B-cell lymphoma (Kochenderfer et al., 2010) and other autoimmune diseases (Jethwa et al., 2014).

To transduce cells with desired genes, viral vectors are usually used as genetic cargos. Genetic transduction is a two-step process: preparing viral vectors and transducing cells to express the desired property. For their superior transduction efficiency, lentiviral and gamma-retroviral vectors are widely used. However, these vectors still currently have some issues, such as the ability to integrate into the host genome running the risk of mutation (Sakuma et al., 2012), which raises safety concerns (Yamashita et al., 2016).

Non-integrative viruses, such as, Sendai virus have proven to be useful for transient transfections, including cellular reprogramming. There are other non-viral approaches. DNA vectors can carry large cargo with less immunotoxicity and are easy to scale up (Hsu and Uludag, 2012). However, their use is less efficient than viral transduction. Non-viral cationic reagents have also been reported to successfully transfect cells with high efficiency (Hsu et al., 2018). Effective transduction using mRNA was also reported for reprogramming terminally differentiated cell to hiPSCs (Warren et al., 2010; Rohani et al., 2016). hiPSCs have also been reprogrammed using recombinant protein (Kim et al., 2009).

As viral vectors and/or DNA integration possess high risk of cancer, some methods for removing these vectors have been developed. One method is the piggyBac, a transposon system that was used to remove tandem Yamanaka factors from iPSCs after reprogramming (Woltjen et al., 2009). After CAR was incorporated into T-cells, the removal of transgenes used another transposon system called Sleeping Beauty, which successfully removed genetic scars from the transduced cells (Huls et al., 2013; Singh et al., 2013). Similarly, Cre excision of reprogramming genes vialoxP sites has also resulted in transgene-free iPSCs (Sommer et al., 2010). Viral vectors deficient in integration are also good candidates for the production of transgene-free CBT by mutating viral integrase (Yáñez-Muñoz et al., 2006).

Genome engineering technologies are other choices for the addition, deletion or correction of genes in the CBT industry (Lombardo et al., 2007). Zinc-finger nucleases (ZFNs), clustered regulatory interspaced short palindromic repeats (CRISPR)/Cas endonucleases, or transcription-activator nucleases (TALENs) (Provasi et al., 2012) are the most commonly used targeting nucleases. CRISPR/Cas system has recently received much attention due to its broad use in the genome engineering of patient cells (Mullard, 2015). ZFNs are also popular for treating graft-versus-host disease in T-cell therapy (Gaj et al., 2013). In cellular reprogramming, a nuclease dead variant of Cas9 with a transcriptional trans-activator was recently used by activating the transcription factors Oct4 and Sox2, which maintained pluripotency and expressed the markers for the three germ layers (Liu et al., 2018).

Genetic modification is considered one of the rate-limiting steps in cell manufacturing industry. Current conventional methods make it more complicated because they are multi-step processes. Genetic modification in planar culture is also expensive, time-consuming and labor-intensive (Hsu et al., 2018).

The bioreactor is a better platform for the production of large-scale genetically modified cells for commercial purposes (Figure 2). In adherent culture, reprogramming factors are generally transfected in order to generate iPSCs, and cells are then expanded in 2D or 3D, which is a two-step process. By integrating the genetic modification step into the bioreactor, a single-step process can be established that allows the production of cells in an automated and closed bioreactor system (Hsu et al., 2018).

In CAR-T CBT application, genetic modification is also a challenging step. After isolating cells from the blood sample of patients, selection and activation are done followed by expansion (Wang and Riviere, 2016). Finally, it is necessary to transduce cells with CAR or any other antigens depending on target diseases (Pampusch et al., 2020). Conventional genetic transduction methods are based on a planar culture wherein each step is carried out in an open culture system posing difficulties in maintaining cGMP.

A few steps have recently been integrated into the bag culture system, wherein selection, activation and expansion can be carried out in a single step using DynaMag™ CTS™ (Hollyman et al., 2009), while the Xuri™ cell expansion system developed by GE Healthcare can expand cells in large numbers (Jin et al., 2012; Somerville et al., 2012). Although washing and concentrating the final product is integrated into the COBE® 2991 system developed by Terumo BCT (Bajgian et al., 2014), the transduction step is not yet integrated into any of the above systems. The integration of the transduction step with the expansion and formulation will make CAR-T CBT straightforward and it is a good platform to carry out these steps in the bioreactor.

Miltenyi Biotech has developed a device called CliniMACS Prodigy™ based on bag culture for CAR-T CBT. In an automated system (Terakura et al., 2012; Casati et al., 2013; Acker et al., 2016), this device integrated major steps in particular cell preparation, selection, activation, transduction, expansion, washing, and formulation. Such integration in the bioreactor will pave the way for the production of closed and automatic cell-based products. This device is also useful for cGMP-compliant production of dendritic cell for cell therapy applications (Erdmann et al., 2018). These systems are now beginning to prove their superiority in implementation of manufacturing protocols and cGMP compliance. Early data also suggests that adoption of such technologies even at an early stage may still be superior to conventional methods and offer returns on investments due to ability to adapt to multiple cell types.
Integration of Expansion and Differentiation in Bioreactors

Current manufacturing practices for cell-based products are multi-step: derivation, expansion, and differentiation. In this process, cells are isolated from any part of a patient's body. In case of MSCs, bone marrow-derived stromal cells are mostly used for clinical application. However, only a very limited number of MSCs can be isolated from specific sources, e.g., MSCs represent only approximately 0.01% of the total fraction of mononuclear cells in the bone marrow (Apel et al., 2013; Orozco et al., 2013). The clinical applications of hMSCs require 1–5 million cells per kilogram of body weight of patient (Meirelles and Nardi, 2003; Connick et al., 2012). In addition, it is important that the derived MSCs can differentiate properly. Therefore, bioprocess development for both expansion and differentiation is equally important.

Several clinical trials using MSCs are taking place worldwide and are increasing day by day. More than 200 clinical trials using MSCs were conducted in 2015 and 2016, which require intensified standardization of production practices (Carlsson et al., 2015). Typically, MSCs are expanded in plate culture and transplanted as whole cells or differentiated into lineage-specific cells for clinical application. However, plate culture is disadvantageous when the clinical trial requires large number of cells (Table 1). Bioreactor expansion of MSCs is required and can provide a large number of cells to exploit the remarkable potential of MSCs in therapeutic applications. When grown as three-dimensional aggregates or spheroids, MSCs show increased angiogenic, anti-inflammatory and immunomodulatory effects and improved stemness and survival after transplantation (Bumpetch et al., 2019). The dynamic culture of MSCs also increases the survivability, proliferation and paracrine effects.

Different configurations of dynamic bioreactors have been developed for MSC expansion according to specific cell types. Among them stirred suspension bioreactors (SSB), rotating wall vessel bioreactors (RWV), and perfusion bioreactors were widely used for the expansion of MSCs (Chen et al., 2006; Rodrigues et al., 2011; Hanley et al., 2014; Lechanteur et al., 2014; Lawson et al., 2016; Egger et al., 2018). To reduce heterogeneous shear stress, NASA has developed a RWV bioreactor (Somerville et al., 2012) which has been shown to be superior to SSB for MSC expansion and differentiation (Chen et al., 2006). Since MSCs have the capacity for multi-lineage differentiation, integration of expansion and differentiation could help to streamline manufacturing processes. Several researchers have reported the integration of expansion and differentiation in the derivation of osteogenic and adipogenic lineages in bioreactors (Chen et al., 2004; Dominici et al., 2006; Duijvestein et al., 2010; Hoch et al., 2012). MSCs have also been expanded and differentiated on microcarriers (see below) in stirred suspension bioreactors for deriving osteogenic lineages (Field et al., 1994; Mazzini et al., 2003; Goh et al., 2013; Shekaran et al., 2016).

As generation of hPSCs from terminally differentiated patient cells is complicated by several steps, the final products are at high risk of contamination. Therefore, as with any pharmaceutical grade medical product, it is also mandatory to maintain cGMP for CBT products (Sensebe et al., 2011; Heathman et al., 2015; Wuchter et al., 2015), which adds many additional complications in the cell production process. It is therefore necessary to standardize the system that can combine all these steps from derivation to final products. Bioreactors are a platform that has shown capability in filling this role (Figure 2).

The bioreactor platform is widely used for the large-scale expansion of hPSC-based CBT production because it is easy to operate and different physicochemical parameters can be regulated in a closed-system. Two groups have shown the bioreactor derivation of PSCs (Fluri et al., 2012; Shafa et al., 2012). Shafa et al. (2012) reported a significantly higher efficiency in bioreactor reprogramming compared to the planar culture. Since mesenchymal-epithelial transition (MET) is an important early step in cellular reprogramming (Samavarchi-Tehrani et al., 2010), transformed fibroblasts moved into the bioreactor form aggregates that are efficiently expanded in the bioreactor. Since fibroblasts are substrate dependent, bioreactor culture can promote the formation of aggregates and therefore cellular reprogramming.

After the bioreactor derivation of hPSCs, expansion and differentiation are the next major steps. A large number of cells are generally required for effective CBT, and can range anywhere from $10^8$ to $10^10$ cells per 70 kg patient (Serra et al., 2012). Obtaining such numbers of cells in plate culture is cumbersome because of growth surface limitation. The surface coating with extracellular matrix (ECM) poses a high risk in the production of clinical products because it is usually derived from animal sources. Recently, a discovery of recombinant ECM (laminin E8 fragment) has been developed that can be used efficiently in clinical applications (Miyazaki et al., 2012).

Automated planar culture systems have been established for the production of clinical-grade hPSCs. CompacT SelecTM developed by TAP Biosystems is one of the notable automated systems for cell production. This system is based on T-flask design, which can accommodate ninety T175 flasks for cell expansion on a large scale. This robotic system can automatically perform all cell culture steps, cell counting, seeding, medium change, passage, plating and transient transfection. Such systems are not used for differentiation, however, because differentiation is a complicated process that needs several components to be added to the culture medium. This mainly disintegrates the process of expansion and differentiation in planar culture.

Except for microcarrier culture, cell expansion in bioreactors does not need surface coating. The bioreactor also provides sufficient availability of growth surface. In general, a single bioreactor (100 ml working volume) is sufficient to provide autologous CBT with a clinically relevant number of cells. For the expansion of hPSCs, several types of bioreactors are used (Wang et al., 2014) (Table 2).

Microcarriers must be coated with ECM for cell attachment in the bioreactor (Olmer et al., 2012; Lam et al., 2014; Fan et al., 2015; Badenes et al., 2016; Kropp et al., 2017) for
anchorage-dependent expansion of hPSCs. Cells are harvested by removing them from the microcarrier using enzymatic treatment after large-scale expansion. Bioreactor expansion of hPSCs on microcarriers is problematic for clinical use, as separating the microcarrier from the final cell harvest requires an additional step. On the other hand, aggregate cultivation in bioreactors may not necessarily require a detachment step for harvesting (Bartosh et al., 2010; Amit et al., 2011; Larijani et al., 2011; Dou et al., 2012; Nath et al., 2018), and clinically relevant cell numbers has been produced as aggregate in a single bioreactor (Haraguchi et al., 2015; Rungarunlert et al., 2016; Nath et al., 2017, 2018) (Table 3).

Size limitation is a major disadvantage in aggregate culture. As the aggregate size increases, the growth potential of the large aggregate decreases due to the limited diffusion of oxygen and nutrients (Nath et al., 2017). Maintenance of aggregate size is therefore an important point in order to maintain a high growth rate and high quality for CBT applications (Dou et al., 2012).

Bioreactor culture is a unique choice for CBT production because differentiation and expansion can be done in the same vessel. Bioreactors have been used to differentiate hPSCs into different cell types, especially for cardiac (Matsuura et al., 2012; Kempf et al., 2015; Rungarunlert et al., 2016), hepatic (Vosough et al., 2013; Park et al., 2014), and neural (Yan et al., 2016) lineages. In order to provide direct methods for clinical applications, it is important to integrate expansion and differentiation, and several reports have recently been published wherein expansion and differentiation have been integrated (Lam et al., 2014; Ting et al., 2014; Fonoudi et al., 2015; Haraguchi et al., 2015). The integration of derivation with expansion and differentiation, however, still faces complications and very few reports are available (Steiner et al., 2010).

Steiner et al. (2010) have reported integrating the derivation, propagation and differentiation of hESCs in the suspension culture where hESCs were isolated from the inner cell mass, and did not involve feeder cells or microcarriers. However, the integration of derivation, expansion and differentiation for personalized medicine, in particular for autologous or allogeneic CBT applications, has still not been achieved. This integration is necessary to overcome multi-step cell processing, which reduces

| Cell types | Seeding density, (cells/mL, 10^5) | Final density, (cells/mL, 10^5) | Culture time (day) | Medium volume, (mL) | Bioreactor types | References |
|------------|----------------------------------|---------------------------------|-------------------|------------------|-----------------|------------|
| hESC       | 3.3                              | 7.9                             | 4                 | 100              | Bioreactor (DASGIP/Eppendorf) | Kempf et al., 2015 |
| hESC       | 0.7                              | 7                               | 5                 | 200              | Gas permeable single use bag (Nipro) | Otsuji et al., 2014 |
| hiPSC      | 3                                | 10                              | 6                 | 100              | Spinner flask (Cellspin, Integra Biosciences) | Haraguchi et al., 2015 |
| hiPSC      | 4                                | 16                              | 5                 | 50               | Spinner flask (Cellspin, Integra Biosciences) | Wang et al., 2013 |
| hiPSC      | 2.5                              | 20                              | 6                 | 60               | Spinner flask (50119114, Thermo Scientific) | Chen et al., 2011 |
| hiPSC      | 4                                | 15                              | 7                 | 100              | Bioreactor (DASGIP/Eppendorf) | Olmer et al., 2012 |
| hiPSC      | 3                                | 12                              | 7                 | 100              | Bioreactor (Cellspin, Integra Biosciences) | Abbasalizadeh et al., 2012 |
| hiPSC      | 10                               | 20                              | 7                 | 100              | Spinner flask (IBS Integra Biosciences) | Zweigerdt et al., 2011 |
| hiPSC      | 1                                | 18                              | 6                 | 50               | Spinner flask (Integra Biosciences) | Amit et al., 2011 |
| hESC       | 10                               | 20                              | 7                 | 50               | Spinner flask (Cellspin, IBS Integra Biosciences) | Singh et al., 2010 |
| hESC       | 0.2                              | 5                               | 6                 | 100              | Bioreactor (NDS Technologies) | Krawetz et al., 2010 |
| hESC       | 6                                | 360                             | 28                | 55               | Slow-turning lateral vessel (Synthecon) | Gerecht-Nir et al., 2004 |
| hiPSC      | 5                                | 36                              | 7                 | 125              | DASbox mini bioreactor system (Eppendorf AG, Hamburg, Germany) | Kropp et al., 2016 |
| hiPSC      | 2                                | 12                              | 7                 | 100              | Spinner flask (Corning) | Kwok et al., 2018 |
| hESC       | 6                                | 35                              | 5                 | 100              | Spinner flask (Belico) | Oh et al., 2009 |
| hESC       | 2.5                              | 3                               | 10                | 125              | Spinner flask (Corning) | Silva et al., 2015 |
| hiPSC      | 5                                | 5                               | 5                 | 100              | Bioreactor (NDS Technologies) | Meng et al., 2017 |
| hiPSC      | 1                                | 45                              | 8                 | 100              | Bioreactor (Able) | Nath et al., 2018 |
the risk of contamination, saves cell processing time and reduces costs for the CBT manufacturing.

REGULATORY CONSTRAINTS IN CBT MANUFACTURING

With the advancement of cell processing facilities, several clinical trials have taken place in recent years using hPSCs (Lebkowski, 2011; Menasché et al., 2015; Schwartz et al., 2015; Trounson and McDonald, 2015; Mandai et al., 2017) which is triggering much attention from regulatory bodies on cGMP implementation in CBT manufacturing (Giancola et al., 2012). Since cell culture media contains various xenogens including source-derived virus and biochemicals (Martin et al., 2005; Cobo et al., 2008), CBT products need to be cultured in the xeno-free condition so that they are free from xeno-mediated infection or immune rejection according to regulatory agencies (Cimino et al., 2017). Currently both hESC and hiPSC lines have been derived following cGMP and deposited into national cell bank from various nations including China, Japan, United States, and United Kingdom, and their efficacy and safety has been tested using standard protocol (Hawkes, 2011; Ilic et al., 2012; Baghbaderani et al., 2015; Wang et al., 2015; Azuma and Yamanaka, 2016; Catapult, 2017). However, their differentiation capability into diverse cell lineages is yet to be tested although a few cell lines have already been tested in cGMP facilities (Kajiwara et al., 2012; Löhle et al., 2012; Heslop et al., 2017; Rao et al., 2018; Blackford et al., 2019; Shafa et al., 2019). Therefore, facilitating cGMP-compliant manufacturing and establishing standard operating procedures (SOP) according to regulatory agencies is a prime concern for CBT products.

cGMP is a regulatory framework overseen at the governmental level meant to establish basic minimum standards in safety, efficacy, and standardization of many types of products. All CBTs must meet regulatory requirements to be approved for sale and marketing. This is the end goal of clinical trials, to make a therapy available for wide scale implementation, and entry into worldwide markets. One of the first considerations is to begin engaging with the national regulatory board as soon as there even a thought about potential commercialization.

Approval from two of the most stringent regulatory organizations: USFDA, and the European Medicines Agency (EMA) that allows for easy entry into virtually every other market in the world (Rehakova et al., 2020). The intended application of human cells, tissues, and cellular and tissue-based products (HCT/P) are regulated by FDA’s Center for Biologics Evaluation and Research (CBER). However, FDA is intrinsically concerned about stem cell-related therapeutic products implementation, transplantation and infusion into patient since the cells may change their cellular properties after being expanded outside of body (Reisman and Adams, 2014). The EMA is generally considered the most stringent and well defined regulatory board for CBTs, and usually, if these standards are met, it will lead to the least problems in transferring to other markets, barring other legal issues such as patents and intellectual property rights.

Without engagement with regulatory boards, the CBT products have less chance of avoiding common pitfalls that have led to efficacious products not making it to market, even with good supporting data. This is important because, as mentioned, regulatory standards can differ across national lines. As the field is relatively new and advancing at a fast pace, regulators have been left to working with companies on a case-by-case basis to establish guidelines, and best practices that are in line with the stringency of cGMP standards in other areas (Bedford et al., 2018). This has led to the publishing of various guidance documents rather than overly strict ordinances, which acknowledge the inherent variability in these products, both between types (protein, whole cell, gene, etc.), and even between lots of the same product (European Medicines Agency, 2020; U.S. Food and Drug Administration, 2020).

It is well understood that CBTs inherently carry a higher level of heterogeneity, and difficult to control factors than chemical reactions that can produce extremely homogenous batches of classic pharmaceuticals. As part of this, regulators such as, Health Canada are often eager to work with potential CBT companies and academic institutions to develop guidelines based on the best current science available, and the unique product under review, while also helping to navigate the difficult regulatory terrain to higher phase studies and commercialization.

The second most important consideration is to hire or assign a team member to focus mainly on the navigation of regulation immediately. It is advisable that this be their main task, as the beginning stages are the most important. In CBTs, it is said that “the process is the product” and if the project is taken too far without this consideration it can be virtually impossible or at least economically unlikely to be able to recover after having to go back to earlier stages because details were overlooked. The unavoidable nature of GMP in CBTs is that even sometimes a seemingly simple laboratory procedure must become a multi-page SOP document covering literally every detail of the procedure. These documents then become the trail of documentation, and the very process itself, which is to be adhered to in manufacturing and available for regulatory review.

It is very important to attempt to begin to think about cGMP-like standards as soon as even the idea of a potential commercialization begins to materialize. Often this can be as early as pre-clinical, depending on the data, though perhaps more reasonably around phase 1 trials. For example, Health Canada requires increasing GMP compliance, and increasingly stringent manufacturing controls as trials advance although a manufacturing establishment license is not required while the product is still under any phase of clinical trials (Government of Canada, 2015). The FDA also requires GMP compliance in Investigational New Drug (IND) assessments at phase 1, and stringency increases in manufacturing establishment licensing from phase 2 onwards (US FDA, 2008). Finally, the EMA requires manufacturing authorization and compliance with established GMP regulations for all stages of clinical trial development, with “inspections performed by a competent authority/qualified person (QP) of a member state” (Bedford et al., 2018).

As one can see, in the United States and Canada an early phase can be “boutique” in having each treatment individually created under standard laboratory proper conditions and very carefully controlled, whereas this is not necessarily the case in...
Europe. Therefore, with increasing enrolment as trials continue, a GMP-like approach should be adopted in every economically and physically feasible manner throughout the process as required. This includes making changes such as using “clinical grade” versus “laboratory grade” reagents, designing a robust manufacturing pipeline, considering quality and assurance guidelines, and creating in-depth documentation to regulatory standards to name merely a few requirements. It should be considered that any change in reagent, manufacturer of said reagents, processes, etc. carries a large weight as there is absolutely a chance of a change in associated outcomes and requirements.

One of the reasons bioreactors and automated processes are extremely useful in meeting GMP standards in CBTs is that, informally, some key aspects can be summarized as: the less manipulations in the process, and the fewer hands that touch to product, the better. Let us recall the phrase “the process is the product,” this is essential to remember for CBTs. If the process is not correctly implemented in a GMP-like fashion, it does not matter if the product works as intended. It will be required to go back the drawing board to make the bio-process compliant. This increases the time and cost even further.

It may be the case that for the near-future CBTs will only be successful in smaller-scale manufacturing, and smaller lots due to the challenges with characterization and standardization associated with whole cell populations. This may require smaller, more flexible operations spread across nations rather than mega-manufacturing centers as is currently the case with standard pharmaceuticals. It is prudent to consider decentralized models of production in order to achieve profitability and market penetration.

CBTs often require more flexibility in production as there are finer windows of effectiveness and therapeutic application, as well as, inherently less ability to control and properly assess safety and efficacy in increasing scale. This may lead to needing to find ways to adapt similar processes across multiple pipelines in order to flexibly meet supply and demand based on various ailments and treatments. The upside of this is that integrated automated processes and bioreactor technologies tend to be far easier to scale up and down as required. Further advances in computing technology, basic biomarker discovery, cell characterization, and onboard or automated monitoring equipment will be essential in decreasing costs and increasing capacity, allowing for CBTs to become more and more ubiquitous in improving human health.

CONCLUDING REMARKS AND FUTURE DIRECTIONS

Application of CBT increases day by day and several clinical studies are continuing to treat incurable diseases. Manufacturing facilities should be compatible with the growing need for cell-based products to meet market demand by providing safe and effective cell-based products. Since current production systems have several disadvantages particularly multi-stage processing, which poses a high risk of contamination, long processing times, and increased production costs, a more straightforward cGMP-compliant system is needed. Bioreactor-based cell production systems can provide cell-based products with single step, easing the practice of cGMP for CBT production. The integration of various steps in bioreactors: derivation, genetic modification, expansion, and differentiation, will pave the way for the future of CBT manufacturing. The integrated production of cell biologics in bioreactor will significantly reduce the risk of contamination, and cell-processing time providing a cost-effective platform for CBTs.

AUTHOR CONTRIBUTIONS

SN and DR perceived the concept and design. SN and LH wrote the manuscript. DR revised and approved the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

SN is partially supported by a Cumming School of Medicine Postdoctoral Fellowship.

REFERENCES

Abbasalizadeh, S., Larijani, M. R., Samadian, A., and Baharvand, H. (2012). Bioprocess development for mass production of size-controlled human pluripotent stem cell aggregates in stirred suspension bioreactor. Tissue Eng. Part C Methods 18, 831–851. doi: 10.1089/tenc.2012.0161

Acker, J. P., Marks, D. C., and Sheffield, W. P. (2016). Quality assessment of established and emerging blood components for transfusion. J. Blood Transfus. 2016:4860284. doi: 10.1155/2016/4860284

Amit, M., Laevsky, I., Miropolsky, Y., Shariki, K., Peri, M., and Itskovitz-Eldor, J. (2011). Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nat. Protoc. 6, 572–579. doi: 10.1038/nprot.2011.325

Apel, M., Brüning, M., Granzin, M., Eslí, M., Stuth, J., Blaschke, J., et al. (2013). Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chem. Eng. Tech. 85, 103–110. doi: 10.1002/cite.201200175

Attwood, S. W., and Edel, M. J. (2019). iPS-Cell technology and the problem of genetic instability-can it ever be safe for clinical use? J. Clin. Med. 8:288. doi: 10.3390/jcm8030288

Azuma, K., and Yamanaka, S. (2016). Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Regen. Ther. 4, 36–47. doi: 10.1016/j.reth.2016.01.009

Badenes, S. M., Fernandes, T. G., Rodrigues, C. A. V., Diogo, M. M., and Cabral, J. M. S. (2016). Microcarrier-based platforms for in vitro expansion and differentiation of human pluripotent stem cells in bioreactor culture systems. J. Biotechnol. 234, 71–82. doi: 10.1016/j.jbiotec.2016.07.002

Baghdadarian, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., et al. (2015). cGMP-Manufactured human induced pluripotent stem cells are available for pre-clinical and clinical applications. Stem Cell Rep. 5, 647–659. doi: 10.1016/j.stemcr.2015.08.015

Bajgain, P., Mucharla, R., Wilson, J., Welch, D., Anurathapan, U., Liang, B., et al. (2014). Optimizing the production of suspension cells using the G-Rex ‘M’ series. Mol. Ther. Methods Clin. Dev. 1:14015. doi: 10.1038/mtm.2014.15
Bartosh, T. J., Ylöstalo, J. H., Mohammadipoor, A., Bazhanov, N., Coble, K., Claypool, K., et al. (2010). Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc. Natl. Acad. Sci. U.S.A. 107, 13724–13729. doi: 10.1073/pnas.1008117107

Bau, C. (2007). Insertional mutagenesis in gene therapy and stem cell biology. Curr. Opin. Hematol. 14, 337–342. doi: 10.1097/MOH.0b013e3282f90001

Bedford, P., Jy, J., Collins, L., and Keizer, S. (2018). Considering Cell Therapy Product “Good Manufacturing Practice” Status. Front. Med. 5:118. doi: 10.3389/fmed.2018.00118

Bellone, G., Turlietti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., et al. (1999). Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic TH2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155, 537–547. doi: 10.1016/S0002-9440(10)65149-8

Bennett, C. (2018). Available online at: https://www.genengnews.com/insights/cell-therapy-manufacturing-the-supply-chain-challenge/ (accessed April, 2020).

Bisson, W. (2008). “Continuous manufacturing ñ the ultra-lean way of manufacturing,” in Proceedings of the ISPE Innovations in Process Technology for Manufacture of APIs and BPCs. Copenhagen.

Blackford, S., Ng, S. S., Segal, J. M., King, A., Austin, A. L., Kent, D., et al. (2019). Validation of current good manufacturing practice compliant human pluripotent stem cell-derived hepatocytes for cell-based therapy. Stem Cells Transl. Med. 8, 124–137. doi: 10.1002/sctm.18-0084

Bunpetch, V., Zhang, Z.-Y., Zhang, X., Han, S., Zongyou, P., Wu, H., et al. (2019). Strategies for MSC expansion and MSC-based microtissue for bone regeneration. Biomaterials 196, 67–79. doi: 10.1016/j.biomaterials.2017.11.023

Carlsson, P. O., Schwarcz, E., Korsgren, O., and Le Blanc, K. (2015). Preserved Xeno-free strategies for safe human mesenchymal stem/stromal cell expansion: supplements and coatings. Stem Cells Int. 2017:6597815. doi: 10.1155/2017/6597815

ClinicalTrials.gov (2020). Available online at: https://clinicaltrials.gov (accessed October 8, 2020).

Cobe, F., Navarro, J. M., Herrera, M. I., Vivo, A., Porcel, D., Hernández, C., et al. (2008). Electron microscopy reveals the presence of viruses in mouse embryonic fibroblasts but neither in human embryonic fibroblasts nor in human mesenchymal cells used for hESC maintenance: toward an implementation of microbiological quality assurance program in stem cell banks. Cloning Stem Cells 10, 65–74. doi: 10.1007/s10483-007-0020-0

Connick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., et al. (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 11, 150–156. doi: 10.1016/S1474-4221(11)70305-2

Cynarski, D. (2018). “Reprogrammed” stem cells implanted into patient with Parkinson’s disease. Nature 563, 1–2. doi: 10.1038/d41586-018-07407-9

Davie, N. L., Brindle, D. A., Culme-Seymour, E. J., and Mason, C. (2012). Streaming cell therapy manufacture. Bioprocess Int. 10, 24–29.

Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317. doi: 10.1016/j.vasurg.2018.08.055905

Dou, X. Q., Yang, X. M., Li, P., Zhang, Z. G., Schönerr, H., Zhang, D., et al. (2012). Novel pH responsive hydrogels for controlled cell adhesion and triggered surface detachment. Soft Matter 8, 9539–9544. doi: 10.1039/C2SM2642K

Dudley, M. E., Wunderlich, J. R., Shelfton, T. E., Even, J., and Rosenberg, S. A. (2003). Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332–342. doi: 10.1097/00002371-200307000-00005

Duijvestein, M., Bos, A. C., Roelofs, H., Wildenberg, M. E., Wendt, B. B., Verspaget, H. W., et al. (2010). Autologous bone marrow-derived mesenchymal stem cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59, 1662–1669. doi: 10.1136/gut.2010.215152

Egger, D., Tripiciano, C., Weber, V., Dominici, M., and Kasper, C. (2018). Dynamic cultivation of mesenchymal stem cell aggregates. Bioengineering 5:48. doi: 10.3390/bioengineering5020048

Erdmann, M., Ulu, U., Wiesinger, M., Brüning, M., Altmann, T., Strasser, E., et al. (2018). Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy. J. Immunol. Methods 463, 89–96. doi: 10.1016/j.jim.2018.09.012

European Medicines Agency (2020). Multidisciplinary: Cell Therapy and Tissue Engineering. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000405.jsp&mdid=WCOB01000158002058a (accessed April 5, 2020).

Fan, Y., Wu, J., Ashok, P., Hsiung, M., and Tzanakakis, E. S. (2015). Production of human pluripotent stem cell therapeutics under defined xeno-free conditions: progress and challenges. Stem Cell Rev. 11, 96–109. doi: 10.1007/s12015-014-9454-x

Feng, Q., Lu, S. J., Klimanskaya, I., Klimanskaya, I., Gomes, I., Kim, D., et al. (2010). Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28, 704–712. doi: 10.1002/stem.321

Field, R. E., Buchanan, J. A., Coppelmanns, M. G., and Aichroth, P. M. (1994). Bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 94, 92–95. doi: 10.1016/j.ijcard.2004.03.034

Fierc Pharma (2016). Available online at: http://www.fiercpharma.com/manufacturing/fda-urges-companies-to-get-on-board-continuous-manufacturing (accessed April 14, 2016).

Fluri, D. A., Tonge, P. D., Song, H., Baptista, R. P., Shakiba, N., Shukla, S., et al. (2012). Derivation, expansion and differentiation of induced pluripotent stem cells in continuous suspension cultures. Nat. Methods 9, 509–516. doi: 10.1038/nmeth.1939

Fonoudi, H., Ansari, H., Abbassalizadeh, S., Larjiani, M. R., Kiani, S., Hashemizadeh, S., et al. (2015). A universal and robust integrated platform for the scalable production of human cardiomycocytes from pluripotent stem cells. Stem Cells Transl. Med. 4, 1482–1494. doi: 10.5966/sctm.2014-0275

Fondi, P., O., Schwarcz, E., Korsgren, O., and Le Blanc, K. (2015). Preserved Xeno-free strategies for safe human mesenchymal stem/stromal cell expansion:
Gaj, T., Gersbach, C. A., and Barbas, C. F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397–405. doi: 10.1016/j.tibtech.2013.04.004

Gajewski, T. F., Schreiber, H., and Fu, Y. X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022. doi: 10.1038/ni.2708

Galat, V., Galat, Y., Peretipchka, M., Jennings, L. J., Iannaccone, P. M., and Hendrix, M. J. (2016). Transgene reactivation in induced pluripotent stem cell derivatives and reversion to pluripotency of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Dev. 25, 1060–1072. doi: 10.1089/scd.2015.0366

Galvaukasauskas, V., Simutis, R., Nath, S. C., and Kino-Oka, M. (2019). Kinetic modeling of human induced pluripotent stem cell expansion in suspension culture. Regen. Ther. 12, 88–93. doi: 10.1016/j.reth.2019.04.007

Garber, K. (2015). RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 33, 890–891. doi: 10.1038/nbt.3127.0

Gee, A. P., Sumstad, D., Stanson, J., Watson, P., Proctor, J., Kadidlo, D., et al. (2008). Gee, A. P., Sumstad, D., Stanson, J., Watson, P., Proctor, J., Kadidlo, D., et al. (2008). Differentiation of human fetal mesenchymal stem cells. Stem Cells Transl. Med. 6, 1321–1331. doi: 10.1002/stem.16-0002

Hoch, A. I., Binder, B. Y., Genetos, D. C., and Leach, J. K. (2012). Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells. PLoS One 7:e55759. doi: 10.1371/journal.pone.0055759

Hucquet, D., Sauget, M., Roussel, S., Malughani, C., Pouthier, F., Morel, P., et al. (2014). Validation of an automated blood culture system for sterility testing of cell therapy products. Cytotherapy 16, 692–698. doi: 10.1016/j.jcyt.2013.09.005

Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cellular therapy. J. Immunother. 32, 169–180. doi: 10.1097/CJF.0b013e318194fe86

Hsu, C. Y. M., and Uludag, H. (2012). Nucleic-acid based gene therapeutics: delivery challenges and modular design of non-viral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. J. Drug Target 20, 301–328. doi: 10.3109/1061186X.2012.655247

Hsu, C. Y. M., Walsh, T., Borys, B., Kallos, M., and Rancourt, D. E. (2018). An integrated approach towards the bio-manufacturing of engineered cell therapy products in a continuous stirred suspension bioreactor. Mol. Ther. Methods Clin. Dev. 9, 376–389. doi: 10.1016/j.omtm.2018.04.007

Huls, M. H., Figliola, M. J., Dawson, M. J., Oliviars, S., Kebriea, P., Shpall, E. J., et al. (2013). Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J. Vis. Exp. 72:e50070. doi: 10.3791/50070

Hunt, C. J. (2011). Cryopreservation of human stem cells for clinical application: a review. Transfus. Med. Hemother. 38, 107–123. doi: 10.1007/100036623

Illic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., et al. (2012). Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy 14, 122–128. doi: 10.1016/j.cytob.2011.12.092

Jenkins, M. J., and Farid, S. S. (2015). Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol. J. 10, 83–95. doi: 10.1002/biot.201400348

Jethwa, H., Adami, A. A., and Maher, J. (2014). Use of gene-modified regulatory T-cells to control autoimmune and allograft immunity: Is now the right time? Clin. Immunol. 150, 51–63. doi: 10.1016/j.clim.2013.11.004

Jin, J., Sabatino, M., Somerville, R., Wilson, J. R., Dudley, M. E., Stroncek, D. F., et al. (2012). Simplified method of the growth of human tumor infiltrating lymphocytes in gas permeable flasks to numbers needed for patient treatment. J. Immunother. 35, 283–292. doi: 10.1097/CJI.0b013e31824e801f

Jozala, A. F., Geraldes, D. C., Tundisi, L. L., Feitosa, V. A., Breyer, C. A., Cardoso, S. L., et al. (2016). Biopharmaceuticals from microorganisms: from production to purification. Braz. J. Microbiol. 47, 51–63. doi: 10.1016/j.bjm.2016.10.007

Kajiwara, M., Aoi, T., Okita, K., Takahashi, R., Inoue, H., Takayama, N., et al. (2012). Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Transfus. Med. Hemother. 39, 125–131. doi: 10.1093/txmh/txs016

Kempf, H., Kropp, C., Olmer, R., Martin, U., and Zweigerdt, R. (2015). Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat. Protoc. 10, 1345–1361. doi: 10.1038/nprot.2015.089

Kerkar, S. P. (2013). Model T cells: a time-tested vehicle for gene therapy. Front. Immunol. 4:304. doi: 10.3389/fimmu.2013.00304

Khss, M. H., Patel, N., Carter, C. S., Murray, P. R., and Read, E. J. (2006). Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method. Transfusion 46, 2071–2082. doi: 10.1111/j.1537-2995.2006.00297

Kikuchi, T., Worgall, S., Singh, R., Moore, M. A., and Crystal, R. G. (2000). Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. J. Immunol. 164, 692–700. doi: 10.4049/jimmunol.164.1.692

Kempf, H., Kropp, C., Olmer, R., Martin, U., and Zweigerdt, R. (2015). Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat. Protoc. 10, 1345–1361. doi: 10.1038/nprot.2015.089

Kerkar, S. P. (2013). Model T cells: a time-tested vehicle for gene therapy. Front. Immunol. 4:304. doi: 10.3389/fimmu.2013.00304

Khss, M. H., Patel, N., Carter, C. S., Murray, P. R., and Read, E. J. (2006). Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method. Transfusion 46, 2071–2082. doi: 10.1111/j.1537-2995.2006.00297

Kikuchi, T., Worgall, S., Singh, R., Moore, M. A., and Crystal, R. G. (2000). Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. J. Immunol. 164, 692–700. doi: 10.4049/jimmunol.164.1.692
Koch, C. M., Reck, K., Shao, K., Lin, Q., Jousset, S., Ziegler, P., et al. (2013). Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res. 23, 248–259. doi: 10.1101/gr.134945.112
Kochenderfer, J. N., and Rosenberg, S. A. (2013). Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267–276. doi: 10.1038/nrclonc.2013.46
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102. doi: 10.1182/blood-2010-04-281931

Krawetz, R., Taiani, J. T., Liu, S., Meng, G., Li, X., Kallos, M. S., et al. (2010). Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. Tissue Eng. Part C Methods 16, 573–582. doi: 10.1089/ten.TEC.2009.0228
Kropp, C., Kempf, H., Hallion, C., Robles-Diaz, D., Franke, A., Schepers, T., et al. (2016). Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single-use stirred tank bioreactors. Stem Cells Transl. Med. 5, 1289–1301. doi: 10.5966/sctm.2015.0253
Kropp, C., Massai, D., and Zweigerdt, R. (2017). Progress and challenges in large-scale expansion of human pluripotent stem cells. Process Biochem. 59, 244–254. doi: 10.1016/j.procbio.2016.09.032
Kurata, H., Takakawa, K., and Tanaka, K. (1994). Vitrification of hematopoietic progenitor cells obtained from human cord blood. Bone Marrow Transplant. 14, 261–263.
Kwock, C., Ueda, Y., Kadar, A., Günther, K., Ergün, S., Heron, A., et al. (2018). Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single-use bioreactors. J. Tissue Eng. Regen. Med. 12, e1076–e1087. doi: 10.1002/tcr.2435
Lai, R. C., Chen, T. S., and Lim, S. K. (2011). Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen. Med. 6, 481–492. doi: 10.2217/rme.11.35
Lai, T., Yang, Y., and Ng, S. K. (2013). Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals 6, 579–603. doi: 10.3390/ph6050579
Lam, A. T., Chen, A. K., Li, J., Birch, W. R., Reuveny, S., and Oh, S. K. (2014). Conjoint propagation and differentiation of human embryonic stem cells to cardiomyocytes in a defined microcarrier spinner culture. Tissue Eng. Part C Methods 20, 1911–1923. doi: 10.1089/scd.2010.0517
Lam, C. M., Reck, K., Shao, K., Lin, Q., Joussen, S., Ziegler, P., et al. (2013). Process development for expansion of human mesenchymal stromal cells expressing anti-CD19 chimeric antigen receptors. Mamm. Genome 24, 1804–1817. doi: 10.1007/s00335-013-9400-4
Larijani, M. R., Seifinejad, A., Pournasr, B., Hajihoseini, V., Hassani, S. N., Lam, A. T., Chen, A. K., Li, J., Birch, W. R., Reuveny, S., and Oh, S. K. (2014). Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors. Stem Cells 30, 570–579. doi: 10.1002/stem.1016
Lombardo, A., Genovese, P., Beausjour, C. M., Colleoni, S., Lee, Y. L., and Kim, K. A. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298–1306. doi: 10.1038/nbt1353
Lou, G., Chen, Z., Zheng, M., and Liu, Y. (2017). Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp. Mol. Med. 49, e346. doi: 10.1038/emm.2017.63
Mandai, M., Watanabe, A., Kurimoto, Y., Hiram, Y., Morinaga, C., Daimon, T., et al. (2017). Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038–1046. doi: 10.1056/NEJMoa1608368
Martin, M. J., Muotri, A., Gage, F., and Yanki, A. (2005). Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11:nm1181.
Matsuura, K., Wada, M., Shimizu, T., Haraguchi, Y., Sato, F., Sugiyama, K., et al. (2012). Creation of human cardiac cell sheets using pluripotent stem cells. Biochem. Biophys. Res. Commun. 425, 321–327. doi: 10.1016/j.bbrc.2012.07.089
Mazzini, L., Fagiolli, F., Boccalletti, R., Marerschi, K., Oliveri, G., Oliveri, C., et al. (2003). Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disorder 4, 158–161. doi: 10.1046/j.1365-2013.2001.01453
Meirelles, L., and Nardi, N. B. (2003). Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br. J. Haematol. 123, 702–711. doi: 10.1046/j.1365-2141.2003.04669.x
Menasché, P., Vanneaux, V., Haggé, A., Bel, A., Cholley, B., Cacciapuoti, I., et al. (2015). Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36, 2011–2017. doi: 10.1093/eurheartj/ehv189
Meng, G., Liu, S., Poon, A., and Rancourt, D. E. (2017). Optimizing human induced pluripotent stem cell expansion in stirred-suspension culture. Stem Cells Dev. 26, 1804–1817. doi: 10.1089/scd.2016.09090
Miyazaki, T., Futaki, S., Suemori, H., Taniguchi, Y., Yamada, M., Kawasaki, M., et al. (2012). Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat. Commun. 3:1236. doi: 10.1038/ncomms2231
Moon, J. H., Lee, J. R., Lee, B. C., Suh, C. S., Kim, S. H., Lim, H. J., et al. (2008). Successful vitrification of human amnion-derived mesenchymal stem cells. Hum. Reprod. 23, 1760–1770. doi: 10.1093/humrep/den202
Mullard, A. (2015). Novartis secures first CRISPR pharma collaborations. Nat. Rev. Drug Discov. 14, 82. doi: 10.1038/nrd4546
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., et al. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26, 101–106. doi: 10.1038/nbt1374
Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T., and Yamanaka, S. (2010). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Science 328, 94–97. doi: 10.1126/science.1184875
Nath, S. C., Tokura, T., Kim, M. H., and Kino-Oka, M. (2018). Botulinum neurotoxin type A for the treatment of amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 19, 11:nm1181.
large-scale human pluripotent stem cell production. *Stem Cell Rep.* 2:746. doi: 10.1016/j.stemcr.2014.04.013

Overton, T. W. (2014). Recombinant protein production in bacterial hosts. *Drug Discov. Today* 19, 590–601. doi: 10.1016/j.drudis.2013.11.008

Pampusch, M. S., Haran, K. P., Hart, G. T., Rakasa, E. G., Rendahl, A. K., Berger, E. A., et al. (2020). Rapid transduction and expansion of transduced T cells with maintenance of central memory populations. *Methods Clin. Dev. Protoc.* 16, 1–10. doi: 10.1084/jomt.2019.09.007

Park, Y., Chen, Y., Or dovas, L., and Verfaillie, C. M. (2014). Hepatic differentiation of human embryonic stem cells on microcarriers. *J. Biotechnol.* 174, 39–48. doi: 10.1016/j.jbiotec.2014.01.025

Psitkun, T., Shen, R. F., and Knepper, M. A. (2004). Identification and proteomic profiling of exosomes in human urine. *Proc. Natl. Acad. Sci. U.S.A.* 101, 13368–13373. doi: 10.1073/pnas.0403453101

PR Newswire (2019). *Global Cell and Gene Therapy Market to Reach $11.96 Billion by 2025*. Available online at: https://www.prnewswire.com/news-releases/global-cell-and-gene-therapy-market-to-reach-11-96-billion-by-2025--300896848.html (accessed August 06, 2019).

Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P. Q., Reik, A., et al. (2013). Illustrating the potency of current Good Manufacturing Practice-compliant induced pluripotent stem cell lines as a source of multiple cell line combinations using standardized protocols. *Cytotherapy* 20, 861–872. doi: 10.1016/j.jcyt.2018.03.037

Rayment, E. A., and Williams, D. J. (2010). Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. *Stem Cells* 28, 996–1004. doi: 10.1002/stem.2204

Reardon, S., and Cyranoski, D. (2014). Japan stem-cell trial stirs envy: researchers watch as Akita University team attempts to restore patients vision by transplanting induced pluripotent stem cells into the retina. *Nature* 515, 278–288. doi: 10.1038/512387a

Rehakova, D., Souralova, T., and Koutna, I. (2020). Clinical-grade human pluripotent stem cells for cell therapy: characterization strategies. *Int. J. Mol. Sci.* 21:E2435. doi: 10.3390/ijms21072435

Reisman, M., and Adams, K. T. (2014). Stem cell therapy: a look at current research, development and clinical evaluation of human pluripotent stem cells for clinical application. *Trends Biotechnol.* 30, 350–359. doi: 10.1016/j.tibtech.2012.03.003

Shafa, M., Day, B., Yamashita, A., Meng, G., Liu, S., Krawetz, R., et al. (2012). Derivation of iPSCs in stirred suspension bioreactors. *Nat. Methods* 9, 465–466. doi: 10.1038/nmeth.1973

Shafa, M., Panchalagam, K. M., Walsh, T., Richardson, T., and Baghbaderani, B. A. (2019). Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes. *Biotechnol. Bioeng.* 116, 3228–3241. doi: 10.1002/bit.27159

Shekaran, A., Lam, A., Sim, E., Jain, L., Jain, L., Wen, J. T. P., et al. (2016). Biodegradable ECM-coated PCL microcarriers support scalable human early MSC expansion and in vivo bone formation. *Cytotherapy* 18, 1332–1344. doi: 10.1016/j.cyt.2016.06.016

Silva, M. V., Rodrigues, A. F., Correia, C., Sousa, M. F. Q., Brito, C., Coroaidinha, A. S., et al. (2015). Robust expansion of human pluripotent stem cells: integration of bioprocess design with transcriptomic and metabolomic characterization. *Stem Cells Transl. Med.* 4, 731–742. doi: 10.5966/sctm.2014.0270

Singh, H., Figiolia, M. J., Dawson, M. J., Olivesas, S., Zhang, L., Yang, G., et al. (2013). Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. *PLoS One* 8:e64138. doi: 10.1371/journal.pone.0064138

Singh, H., Mok, P., Balakrishnan, T., Rahmat, S. N., and Zweigertd, R. (2010). Upscaling single cell-inoculated suspension culture of human embryonic stem cells. *Stem Cell Res.* 4, 165–179. doi: 10.1016/j.scr.2010.03.001

Somerville, R. P., Devillier, L., Parkhurst, M. R., Rosenberg, S. A., and Dudley, M. E. (2012). Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. *J. Transl. Med.* 10:69. doi: 10.1186/1479-5876-10-69

Sommer, C. A., Sommer, A. G., Longmire, T. A., Christodoulou, C., Thomas, D. D., Gostissa, M., et al. (2010). Excision of reprogramming transgenes improves the differentiation potential of iPSCs generated with a single excisable vector. *Stem Cells* 28, 66–74. doi: 10.1002/stem.205

Song, X. T. (2013). Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers. *Discov. Med.* 16, 261–266.

Steiner, D., Khaner, H., Cohen, M., Even-Ram, S., Gil, Y., Isyksjon, P., et al. (2010). Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension. *Nat. Biotechnol.* 28, 361–364. doi: 10.1038/nbt.1616

Sterling, J. (2018). Available online at: https://www.genengnews.com/insights/scaling-up-cell-therapy-manufacturing/ (accessed April, 2020).

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872. doi: 10.1016/j.cell.2007.11.019

Taylor, C. J., Bolton, E. M., Pocock, S., Sharples, L. D., Pedersen, R. A., and Taylor, J. A. (2005). Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. *Lancet* 366, 2019–2025. doi: 10.1016/S0140-6736(05)67813-0

Tekoah, Y., Shulman, A., Kizhner, T., Ruderman, I., Fux, L., Nataf, Y., et al. (2015). Large-scale production of pharmaceutical proteins in plant cell culture-the Protolux Experience. *Plant Biotechnol. J.* 13, 1199–1208. doi: 10.1111/pbi.12428

Tetsuka, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., and Riddel, S. R. (2012). Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. *Blood* 119, 72–82. doi: 10.1182/blood-2011-07-366419
Thirumala, S., Goebel, W. S., and Woods, E. J. (2009). Clinical grade adult stem cell banking. *Organogenesis* 5, 143–154. doi: 10.4161/org.5.3.98113

Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147. doi: 10.1126/science.282.5391.1145

Ting, S., Chen, A., Reuveny, S., and Oh, S. K. (2014). An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures. *Stem Cell Res.* 13, 202–213. doi: 10.1016/j.scr.2014.06.002

Trounson, A., and McDonald, C. (2015). Stem cell therapies in clinical trials: progress and challenges. *Cell Stem Cell* 17, 11–22. doi: 10.1016/j.stem.2015.06.007

U.S. Food and Drug Administration (2020). *US FDA Guidance for Industry: CGMP for Phase 1 Investigational Drugs Regulation (EU) No 536/2014, Article 61(1)*. Available online at: https://www.fda.gov/downloads/drugs/guidances/ucm070273.pdf (accessed April 6, 2020).

Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., and Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9, 654–659. doi: 10.1038/nclb1596

Wang, X., and Rivière, I. (2016). Clinical manufacturing of CAR T cells: foundation of a promising therapy. *Mol. Ther. Oncolyt.* 3, 1015. doi: 10.1038/mtol.2016.15

Wang, Y., Cheng, L., and Gerecht, S. (2014). Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013. *Ann. Biomed. Eng.* 42, 1357–1372. doi: 10.1007/s10439-013-0921-4

Yehezkel, S., Rebibo-Sabbah, A., Segev, Y., Tzukerman, M., Shaked, R., Huber, I., et al. (2011). Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. *Epigenetics* 6, 63–75. doi: 10.4161/epi.6.1.13390

Zeng, X. (2007). Human embryonic stem cells: mechanisms to escape replicative senescence? *Stem Cell Rev.* 3, 270–279. doi: 10.1007/s12920-007-9005-x

Yehezkel, S., Rebibo-Sabbah, A., Segev, Y., Tzukerman, M., Shaked, R., Huber, I., et al. (2011). Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. *Epigenetics* 6, 63–75. doi: 10.4161/epi.6.1.13390

Zimmermann, A., Preymat-Seauve, O., Tiercy, J. M., Krause, K. H., and Villard, J. (2012). Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. *Stem Cells Dev.* 21, 2364–2373. doi: 10.1089/scd.2012.0088

Zweigerdt, R., Olmer, R., Singh, H., Haverich, A., and Martin, U. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458, 766–770. doi: 10.1038/nature07863

Wachtler, P., Bieback, K., Schrezenmeier, H., Bornhäuser, M., Müller, L. P., Böning, H., et al. (2015). Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. *Cytotherapy* 17, 128–139. doi: 10.1016/j.jcyt.2014.04.002

Wan, Y., Yin, L., Bai, D., Gu, Q., Han, W., Wang, L., et al. (2015). Generation of functional hepatocyte-like cells from human pluripotent stem/stromal cells: a new therapeutic paradigm. *Biomark. Res.* 7:8. doi: 10.1186/s40364-019-0159-x

Wolten, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458, 766–770. doi: 10.1038/nature07863

Wuchter, P., Bieback, K., Schrezenmeier, H., Bornhäuser, M., Müller, L. P., Böning, H., et al. (2015). Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. *Cytotherapy* 17, 128–139. doi: 10.1016/j.jcyt.2014.04.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Nath, Harper and Rancourt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.